Cancer Supportive Care Drugs Market Size, Share & Trends Report

Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Antiemetics, Bisphosphonates, Opioids, NSAIDs), By Region (North America, Europe), And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-2-68038-529-8
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market Segmentation

  • Cancer Supportive Care DrugsTherapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    • G-CSFs (Granulocyte-colony Stimulating Factors)
    • ESAs (Erythropoiesis Stimulating Agents)
    • Anti-emetics
    • Bisphosphonates
    • Opioids
    • NSAIDs and Others
  • Cancer Supportive Care DrugsRegional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Cancer Supportive Care Drugs Market, By Therapeutic Class
        • G-CSFs (Granulocyte-colony Stimulating Factors)
        • ESAs (Erythropoiesis Stimulating Agents)
        • Anti-emetics
        • Bisphosphonates
        • Opioids
        • NSAIDs and others
      • U.S.
        • U.S. Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Canada
        • Canada Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
    • Europe
      • Europe Cancer Supportive Care Drugs Market, By Therapeutic Class
        • G-CSFs (Granulocyte-colony Stimulating Factors)
        • ESAs (Erythropoiesis Stimulating Agents)
        • Anti-emetics
        • Bisphosphonates
        • Opioids
        • NSAIDs and others
      • U.K.
        • U.K. Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Germany
        • Germany Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Spain
        • Spain Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • France
        • France Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Italy
        • Italy Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Sweden
        • Sweden Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Norway
        • Norway Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Denmark
        • Denmark Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
    • Asia Pacific
      • Asia Pacific Cancer Supportive Care Drugs Market, By Therapeutic Class
        • G-CSFs (Granulocyte-colony Stimulating Factors)
        • ESAs (Erythropoiesis Stimulating Agents)
        • Anti-emetics
        • Bisphosphonates
        • Opioids
        • NSAIDs and others
      • Japan
        • Japan Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • China
        • China Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • India
        • India Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • South Korea
        • South Korea Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Australia
        • Australia Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Thailand
        • Thailand Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
    • Latin America
      • Latin America Cancer Supportive Care Drugs Market, By Therapeutic Class
        • G-CSFs (Granulocyte-colony Stimulating Factors)
        • ESAs (Erythropoiesis Stimulating Agents)
        • Anti-emetics
        • Bisphosphonates
        • Opioids
        • NSAIDs and others
      • Brazil
        • Brazil Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Mexico
        • Mexico Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Argentina
        • Argentina Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
    • MEA
      • MEA Cancer Supportive Care Drugs Market, By Therapeutic Class
        • G-CSFs (Granulocyte-colony Stimulating Factors)
        • ESAs (Erythropoiesis Stimulating Agents)
        • Anti-emetics
        • Bisphosphonates
        • Opioids
        • NSAIDs and others
      • South Africa
        • South Africa Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • UAE
        • UAE Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Saudi Arabia
        • Saudi Arabia Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others
      • Kuwait
        • Kuwait Cancer Supportive Care Drugs Market, By Therapeutic Class
          • G-CSFs (Granulocyte-colony Stimulating Factors)
          • ESAs (Erythropoiesis Stimulating Agents)
          • Anti-emetics
          • Bisphosphonates
          • Opioids
          • NSAIDs and others

Cancer Supportive Care Drugs Market Dynamics

Driver: Large Number of Side Effects Associated with the Cancer Treatment

Targeted cancer therapies have increased significantly in the last decade, including hormonal and monoclonal antibody therapies for various cancers. However, the lack of availability of newly developed targeted therapies is a major restraint in the market. As targeted drugs become more preferred over chemotherapy, the growth prospects of the cancer-supportive care market will eventually diminish. Companies are investing in targeted cancer treatments and immunotherapies to specifically destroy tumor cells, moving away from traditional chemotherapy.

Restraint: Rising Demand for Targeted Therapies for the Treatment of Cancer in Developed Countries

Traditional cancer treatment methods not only focus on cancer cells but also harm healthy cells. However, over the past decade, the number of targeted therapies for cancer care has significantly increased. Hormonal and monoclonal antibody therapies have emerged as feasible treatments for various cancers including breast, prostate, colorectal, and lung cancer. The major challenge faced by this market is the limited availability of newly developed targeted therapies for the treatment of various cancer indications. As targeted drugs are becoming more preferred than chemotherapy, the growth prospects of the cancer-supportive care market will eventually reduce. In addition, companies are now investing in targeted cancer treatments and immunotherapies to destroy tumor cells specifically rather than using traditional chemotherapy.

Opportunity:  Development of Safer Alternatives for Erythropoiesis-Stimulating Agents and Pain Management Products and Launch of Biosimilar

Antibody therapies have emerged as cancer treatments, but the market faces the challenge of limited targeted therapies. Companies are now investing in targeted treatments to destroy tumor cells specifically. Biosimilar adoption presents an opportunity for key market players, and patent expiration of blockbuster drugs has provided an opportunity for manufacturers to venture into the biosimilar market. Teva's Granix provides new treatment options for patients, and the launch of biosimilars provides opportunities for growth in the cancer-supportive care market.

What Does This Report Include?

This section will provide insights into the contents included in this cancer supportive care drugs market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Cancer supportive care drugs market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Cancer supportive care drugs market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon